These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 28258701)

  • 61. TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis.
    Zhou X; Mao Y; Zhu J; Meng F; Chen Q; Tao L; Li R; Fu F; Liu C; Hu Y; Wang W; Zhang H; Hua D; Chen W; Zhang X
    Oncotarget; 2016 Oct; 7(41):67196-67211. PubMed ID: 27626488
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression of costimulatory molecule B7-H4 in human malignant tumors.
    Zheng X; Li XD; Wu CP; Lu BF; Jiang JT
    Onkologie; 2012; 35(11):700-5. PubMed ID: 23147549
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Dual Role of Treg in Cancer.
    Frydrychowicz M; Boruczkowski M; Kolecka-Bednarczyk A; Dworacki G
    Scand J Immunol; 2017 Dec; 86(6):436-443. PubMed ID: 28941312
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer.
    Fauci JM; Straughn JM; Ferrone S; Buchsbaum DJ
    Gynecol Oncol; 2012 Nov; 127(2):420-5. PubMed ID: 22910694
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells.
    Chen Y; Yang C; Xie Z; Zou L; Ruan Z; Zhang X; Tang Y; Fei L; Jia Z; Wu Y
    Kidney Int; 2006 Dec; 70(12):2092-9. PubMed ID: 17051145
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
    Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
    Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
    [TBL] [Abstract][Full Text] [Related]  

  • 67. B7-H4 promotes tumor growth and metastatic progression in lung cancer by impacting cell proliferation and survival.
    Zhang X; Cai L; Zhang G; Shen Y; Huang J
    Oncotarget; 2017 Mar; 8(12):18861-18871. PubMed ID: 28061481
    [TBL] [Abstract][Full Text] [Related]  

  • 68. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 69. B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice.
    Lee IF; Wang X; Hao J; Akhoundsadegh N; Chen L; Liu L; Langermann S; Ou D; Warnock GL
    Cell Immunol; 2013 Mar; 282(1):1-8. PubMed ID: 23623902
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regulatory T cells, as a target in anticancer immunotherapy.
    Enokida T; Nishikawa H
    Immunotherapy; 2017 Jun; 9(8):623-627. PubMed ID: 28653572
    [No Abstract]   [Full Text] [Related]  

  • 71. Clinical significance of the B7-H4 as a novel prognostic marker in breast cancer.
    Huang H; Li C; Ren G
    Gene; 2017 Aug; 623():24-28. PubMed ID: 28412458
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer.
    Si S; Wang L; Cao H; Xu Y; Zhan Q
    BMC Cancer; 2022 Feb; 22(1):211. PubMed ID: 35219310
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The characteristic expression of B7-H3 and B7-H4 in liver biopsies from patients with HBV-related acute-on-chronic liver failure.
    Guo G; Cao D; Xu H; Ruan Z; Fei L; Xie Z; Wu Y; Chen Y
    Pathol Int; 2012 Oct; 62(10):665-74. PubMed ID: 23005593
    [TBL] [Abstract][Full Text] [Related]  

  • 74. V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases.
    Vaishnav J; Khan F; Yadav M; Parmar N; Buch H; Jadeja SD; Dwivedi M; Begum R
    Immunobiology; 2022 Nov; 227(6):152274. PubMed ID: 36095871
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
    Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
    Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases.
    Qian Y; Sang Y; Wang FX; Hong B; Wang Q; Zhou X; Weng T; Wu Z; Zheng M; Zhang H; Yao H
    Oncotarget; 2016 Nov; 7(44):72242-72249. PubMed ID: 27750217
    [TBL] [Abstract][Full Text] [Related]  

  • 77. B7-H4's role "beyond the tumor".
    Yu N; Li X; Zheng S; Li X
    Inflammation; 2013 Aug; 36(4):941-7. PubMed ID: 23605559
    [TBL] [Abstract][Full Text] [Related]  

  • 78. B7-H4 expression in human infiltrating ductal carcinoma‑associated macrophages.
    Liu L; Li D; Chen S; Zhao R; Pang D; Li D; Fu Z
    Mol Med Rep; 2016 Sep; 14(3):2135-42. PubMed ID: 27430170
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 80. B7-H4 induces donor-specific tolerance in mouse islet allografts.
    Wang X; Hao J; Metzger DL; Mui A; Ao Z; Verchere CB; Chen L; Ou D; Warnock GL
    Cell Transplant; 2012; 21(1):99-111. PubMed ID: 21929869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.